Competitive Grants Program
Pfizer supports the global healthcare community’s independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.
Pfizer’s competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a specific area of interest and sets timelines for review and approval. Organizations are invited to submit an application addressing the specific gaps in research, practice or care as outlined in the specific RFP. The grant requester (and ultimately the grantee) is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements.
Sign up to receive all grant announcements, including Request for Proposal (RFP) postings.
Sign Up for Alerts DetailsTitle Grant Type Focus Area Country Application Due Date Optimizing Antimicrobial Stewardship (AMS) Interventions and Outcomes in Clinical Outcomes, Optimal Use and Resource UtilizatioRelease Date:Research Inflammation & Immunology China Optimizing Disease Management to Improve Alopecia Areata Quality of CareRelease Date:Quality Improvement Inflammation & Immunology China Research on Exploring Disease Assessment and Prioritizing Systematic Treatment for VitiligoRelease Date:Research Inflammation & Immunology China Quality Improvement in Molecular Testing Pathways for Metastatic Colorectal Cancer (mCRC)Release Date:Partner: American Society for Clinical Pathology (ASCP)Quality Improvement Oncology USA Personalized monitoring&treatment for HR+, HER2- mBC patients treated w CDK4/6i: incorporating Patient complexity risk factorsRelease Date:Quality Improvement, Research Oncology Italy Providing Appropriate Medical Care for IBD PatientsRelease Date:Partner: Japanese Society for Inflammatory Bowel Disease (JSIBD)Quality Improvement Inflammation & Immunology Japan Administration of brentuximab vedotin alone or in combination with other approved agents in pre and/or peri CAR-TRelease Date:Research Oncology USA Fostering Educational Initiatives for ALK+ Metastatic Non-Small Cell Lung Cancer(mNSCLC) Tyrosine Kinase Inhibitors(TKI) TherapyRelease Date:Education Oncology Canada Title Grant Type Focus Area Country Application Due Date Closing Knowledge Gaps in Transthyretin Cardiomyopathy (ATTR-CM)Release Date:Education Rare Disease USA Hereditary Transthyretin Amyloidosis Research in ChinaRelease Date:Research Rare Disease China Advances in Immuno-Oncology Therapy in Urothelial CancerRelease Date:Education Oncology Japan RWD in the management of MDR BacteRial severe InfEctions and invasive Fungal disease, ITalian experiencesRelease Date:Research Hospital Italy Quantifying the Socio-Economic Burden of Disease for Dermatology Patients and CaregiversRelease Date:Research Inflammation & Immunology Argentina, Australia, Austria, Belgium, Brazil, Canada, Czech Republic, Denmark, Finland, France, Germany, Greece, Ireland, Israel, Italy, Japan, Korea, Netherlands, Norway, Poland, Portugal, Romania, Russia, Slovakia (Slovak Republic), Spain, Sweden, Switzerland, Turkey, United Kingdom Improving Treatment Environment for Acute LeukemiaRelease Date:Education Oncology Japan Transthyretin Amyloid Cardiomyopathy (ATTR-CM) ResearchRelease Date:Research Rare Disease USA Transthyretin Cardiac Amyloidosis Fellowship - United StatesRelease Date:Fellowship Rare Disease USA Applying Patient-Reported Outcomes in Oncology Patient Care Using Quality Improvement and Implementation Science StrategiesQuality Improvement Oncology USA Understanding and Mitigating Cardiovascular Risk in Patients with Prostate CancerQuality Improvement Oncology USA Cardiac Amyloidosis Mentor mATTch pRogramEducation Rare Disease USA Knowledge Gaps in Testing, Diagnosis and Treatment of COVID-19Release Date:Education Hospital USA